YahooAugust 28, 2026 at 6:15 AM NY7 days ago
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential...
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
Which dow jones stocks are moving on Friday?
ChartMill1 hour ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill1 hour ago
Sector Update: Financial
Yahoo3 hours ago
Should You Buy, Sell or Hold PVH Stock Post Q2 Earnings?
Yahoo3 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo3 hours ago